VTE risk assessment in cancer

C. Ay; I. Pabinger

doi:10.5482/HAMO-14-11-0066

Phlebologie, Table of Contents

Phlebologie 2016; 45(03): 140-145
DOI: 10.5482/HAMO-14-11-0066

Review article

Schattauer GmbH

VTE risk assessment in cancer

Who needs prophylaxis and who does not?VTE-Risikobeurteilung bei KrebserkrankungenWer braucht eine Thromboseprophylaxe und wer nicht?

Authors

C. Ay

¹Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Austria
I. Pabinger

¹Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Austria

Abstract

Summary

Venous thromboembolism (VTE) in patients with cancer is associated with an increased morbidity and mortality, and its prevention is of major clinical importance. However, the VTE rates in the cancer population vary between 0.5–20 %, depending on cancer-, treatment- and patient-related factors. The most important contributors to VTE risk are the tumour entity, stage and certain anticancer treatments. Cancer surgery represents a strong risk factor for VTE, and medical oncology patients are at increased risk of developing VTE, especially when receiving chemotherapy or immunomodulatory drugs. Also biomarkers have been investigated for their usefulness to predict risk of VTE (e.g. elevated leucocyte and platelet counts, soluble P-selectin, D-dimer, etc.). In order to identify cancer patients at high risk of VTE and to improve risk stratification, risk assessment models have been developed, which contain both clinical parameters and biomarkers. While primary thromboprophylaxis with low-molecular- weight-heparin (LMWH) is recommended postoperatively for a period of up to 4 weeks after major cancer surgery, the evidence is less clear for medical oncology patients. Thromboprophylaxis in hospitalized medical oncology patients is advocated, and is based on results of randomized controlled trials which evaluated the efficacy and safety of LMWH for prevention of VTE in hospitalized medically ill patients. In recent trials the benefit of primary thromboprophylaxis in cancer patients receiving chemotherapy in the ambulatory setting has been investigated. However, at the present stage primary thromboprophylaxis for prevention of VTE in these patients is still a matter of debate and cannot be recommended for all cancer outpatients.

Zusammenfassung

Venöse Thromboembolien (VTE) bei Krebserkrankungen führen zu einer erhöhten Morbidität und Mortalität. Daher ist ihre Prävention von großer klinischer Bedeutung. Die VTERate bei Krebspatienten variiert zwischen 0.5–20 % – in Abhängigkeit von Tumor-, Behandlungs- und Patienten-spezifischen Risikofaktoren. Auch die Rolle von verschiedenen Laborparametern und Biomarkern (z.B. erhöhte Thrombozyten und leucozyten, solubles P-Selektin, D-dimer, etc.) für die Vorhersage des Auftretens einer VTE wurde in rezenten Studien untersucht. Um Krebspatienten mit dem höchsten VTE-Risiko zu identifizieren und die Risikostratifizierung zu optimieren, sind Risiko-Scores entwickelt worden, die sowohl klinische Parameter als auch Laborparameter beinhalten. Während eine primäre Thromboseprophylaxe mit niedermolekularen Heparinen (NMH) postoperativ nach großen tumorchirurgischen Operationen für eine Dauer von etwa 4 Wochen empfohlen ist, gibt es keine eindeutige Evidenz für eine routinemäßige medikamentöse Thromboseprophylaxe für “internistische” Krebspatienten. Bei stationären Krebspatienten mit einer akut internistischen Erkrankung ist jedenfalls eine Thromboseprophylaxe zu befürworten. Im ambulanten Setting wird die Durchführung einer primären Thromboseprophylaxe bei Patienten diskutiert, die eine Chemotherapie erhalten.

Keywords

Venous thromboembolism - cancer - hypercoagulability - risk factors - thromboprophylaxis

Schlüsselwörter

Venöse Thromboembolie - Krebs - Hyperkoagulabilität - Risikofaktor - Thromboseprophylaxe

Full Text

References

References
1 Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hämostaseologie 2012; 32: 115-125.
2 Heit JA. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-1248.
3 Spencer FA, Lessard D, Emery C. et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007; 167: 1471-1475.
4 Khorana AA, Francis CW, Culakova E. et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339-2346.
5 Khorana AA, Francis CW, Culakova E. et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-490.
6 Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-579.
7 Stein PD, Beemath A, Meyers FA. et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60-68.
8 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012; 09: e1001275.
9 Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013; 119: 648-655.
10 Moore RA, Adel N, Riedel E. et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29: 3466-3473.
11 Ay C, Vormittag R, Dunkler D. et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27: 4124-4129.
12 Blom JW, Vanderschoot JP, Oostindier MJ. et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 04: 529-535.
13 Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol 2009; 22: 9-23.
14 Chew HK, Wun T, Harvey D. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-64.
15 Dickmann B. et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013; 98: 1309-14.
16 Pabinger I, Ay C. Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?. Hämostaseologie 2012; 32: 132-137.
17 Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013; 122: 2011-2018.
18 Ahlbrecht J. et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2012; 30: 3870-3875.
19 Blom J, Doggen C. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722.
20 Trinh VQ. et al. Venous thromboembolism after major cancer surgery: Temporal trends and patterns of care. JAMA Surg 2014; 149: 43-9.
21 Kröger K. et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17: 297-303.
22 Rajkumar SV. et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
23 Rajkumar SV. et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
24 Scappaticci F. et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
25 Mandala M. et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the “SENDO experience”. Ann Oncol 2012; 23: 1416-1421.
26 Tesselaar M. et al. Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 2004; 40: 2253-2259.
27 Bohlius J. et al. Erythropoietin or darbepoetin for patients with cancer – meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009 08.
28 Königsbrügge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res 2014; 133 (Suppl. 02) S39-S43.
29 Numico G. et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005; 103: 994-999.
30 Königsbrügge O. et al. Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism. J Thromb Haemost 2013; 11: 1993-2000.
31 Ay C, Pabinger I. Tests predictive of thrombosis in cancer. Thromb Res 2010; 125 (Suppl. 02) S12-S15.
32 Ay C. et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112: 2703-2708.
33 Vormittag R. et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29: 2176-2181.
34 Ay C. et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29: 2099-2103.
35 Thaler J. et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012; 10: 1363-1370.
36 Thaler J, Ay C, Pabinger I. Clinical significance of circulating microparticles for venous thromboembolism in cancer patients. Hämostaseologie 2012; 32: 127-131.
37 Thaler J. et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest 2013; 43: 277-285.
38 Langer F, Bokemeyer C. Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hämostaseologie 2012; 32: 95-104.
39 Kanz R, Vukovich T, Vormittag R. et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011; 09: 57-63.
40 Riedl J. et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer: results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost 2014; 111: 670-678.
41 Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis. Hämostaseologie 2014; 34: 54-62.
42 Khorana AA, Kuderer NM, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
43 Ay C, Dunkler D, Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377-5382.
44 Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients – risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108: 1042-1048.
45 Bergqvist D. et al. ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-980.
46 Rasmussen MS. et al. FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 04: 2384-2390.
47 Kakkar VV. et al. CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 08: 1223-1229.
48 Farge D, Debourdeau P, Beckers M. et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11: 56-70.
49 Lyman GH. et al. American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2189-2204.
50 Di Nisio M, Carrier M, Lyman GH, Khorana AA. Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1746-1749.
51 Carrier M, Khorana AA, Moretto P. et al. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 2014; 127: 82-6 e1.
52 Kahn SR. et al. Am College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis. Chest 2012; 141 (Suppl. 02) e195S-e226S.
53 Agnelli G, Gussoni G, Bianchini C. et al. PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 943-949.
54 Agnelli G, George DJ, Kakkar AK. et al. SAVEONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601-609.
55 Perry JR. et al. PRODIGE: a randomized placebocontrolled trial of dalteparin low-molecularweight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 08: 1959-1965.
56 Maraveyas A. et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48: 1283-1292.
57 Riess H, Pelzer U, Optiz B. et al. A prospective, randomizedtrial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. Final Results of the CONKO-004 trial. J Clin Oncol 2010; 28 (Suppl. 15) 4033.
58 Larocca A, Cavallo F, Bringhen S. et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119: 933-939.
59 Palumbo A. et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 29: 986-993.
60 Khorana AA, Otten HM, Zwicker JI. et al. Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1928-1931.